TY - JOUR
T1 - Inflammatory markers of CRP, IL6, TNFα, and Soluble TNFR2 and the risk of ovarian cancer
T2 - A meta-analysis of prospective studies
AU - Zeng, Fangfang
AU - Wei, Huishan
AU - Yeoh, Engkiong
AU - Zhang, Zheqing
AU - Ren, Ze Fang
AU - Colditz, Graham A.
AU - Tworoger, Shelley S.
AU - Su, Xuefen
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/8
Y1 - 2016/8
N2 - Background: There has been growing evidence showing that inflammatory markers play an important role in the development of ovarian cancer. We conducted a meta-analysis on the associations between circulating levels of C-reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and soluble TNFα receptor 2 (TNFR2), and the risk of ovarian cancer. Methods: A systematic search of PubMed and EMBASE up until January 19, 2016 was conducted to retrieve prospective studies. The summary risk estimates were pooled using random-effects models. The dose-response relationship was assessed using generalized least-squares trend estimation. Results: Seven nested case-control studies and one prospective cohort study were included in the review. For circulating CRP, women in the highest category had a significantly increased risk of ovarian cancer than women in the lowest category, with no significant between-study heterogeneity [pooled relative risk (RR)=1.91; 95% confidence intervals (CI) 1.51-2.40; P < 0.001; I2 = 0.0%]. Influence analyses further supported this positive association. A positive dose-response relationship was also observed (pooled RR =1.15;95%CI, 1.03-1.30 per 5mg/L of CRP). Publication bias was found. However, the association persisted after correction using the trim-and-fill method. No significant association was observed for circulating IL6, TNFα, and soluble TNFR2. Conclusion: This meta-analysis provides evidence that elevated levels of CRP, but not circulating IL6, TNFα, or soluble TNFR2, are significantly associated with an increased risk of ovarian cancer. Impact: These results suggest that circulating CRP may play a role in the etiology of ovarian cancer.
AB - Background: There has been growing evidence showing that inflammatory markers play an important role in the development of ovarian cancer. We conducted a meta-analysis on the associations between circulating levels of C-reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and soluble TNFα receptor 2 (TNFR2), and the risk of ovarian cancer. Methods: A systematic search of PubMed and EMBASE up until January 19, 2016 was conducted to retrieve prospective studies. The summary risk estimates were pooled using random-effects models. The dose-response relationship was assessed using generalized least-squares trend estimation. Results: Seven nested case-control studies and one prospective cohort study were included in the review. For circulating CRP, women in the highest category had a significantly increased risk of ovarian cancer than women in the lowest category, with no significant between-study heterogeneity [pooled relative risk (RR)=1.91; 95% confidence intervals (CI) 1.51-2.40; P < 0.001; I2 = 0.0%]. Influence analyses further supported this positive association. A positive dose-response relationship was also observed (pooled RR =1.15;95%CI, 1.03-1.30 per 5mg/L of CRP). Publication bias was found. However, the association persisted after correction using the trim-and-fill method. No significant association was observed for circulating IL6, TNFα, and soluble TNFR2. Conclusion: This meta-analysis provides evidence that elevated levels of CRP, but not circulating IL6, TNFα, or soluble TNFR2, are significantly associated with an increased risk of ovarian cancer. Impact: These results suggest that circulating CRP may play a role in the etiology of ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=84982973874&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-16-0120
DO - 10.1158/1055-9965.EPI-16-0120
M3 - Review article
C2 - 27277846
AN - SCOPUS:84982973874
SN - 1055-9965
VL - 25
SP - 1231
EP - 1239
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 8
ER -